Stifel Financial Corp Decreases Holdings in Mesa Laboratories, Inc. (NASDAQ:MLAB)

Stifel Financial Corp reduced its position in Mesa Laboratories, Inc. (NASDAQ:MLAB) by 16.8% during the 3rd quarter, Holdings Channel.com reports. The firm owned 3,252 shares of the medical instruments supplier’s stock after selling 655 shares during the period. Stifel Financial Corp’s holdings in Mesa Laboratories were worth $422,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in MLAB. Quadrature Capital Ltd acquired a new stake in Mesa Laboratories in the third quarter worth about $221,000. PDT Partners LLC acquired a new position in shares of Mesa Laboratories during the third quarter valued at about $295,000. Captrust Financial Advisors purchased a new position in shares of Mesa Laboratories in the 3rd quarter valued at approximately $207,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Mesa Laboratories by 20.3% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 10,103 shares of the medical instruments supplier’s stock worth $1,312,000 after purchasing an additional 1,708 shares in the last quarter. Finally, Public Sector Pension Investment Board grew its position in Mesa Laboratories by 1.8% during the 3rd quarter. Public Sector Pension Investment Board now owns 11,461 shares of the medical instruments supplier’s stock worth $1,488,000 after purchasing an additional 200 shares during the last quarter. 90.60% of the stock is owned by institutional investors and hedge funds.

Mesa Laboratories Price Performance

Shares of NASDAQ MLAB opened at $133.06 on Friday. Mesa Laboratories, Inc. has a 52 week low of $83.68 and a 52 week high of $141.17. The company has a quick ratio of 0.51, a current ratio of 0.70 and a debt-to-equity ratio of 0.65. The firm has a market cap of $722.65 million, a P/E ratio of -2.92 and a beta of 0.86. The business’s 50 day moving average price is $120.61 and its 200 day moving average price is $116.91.

Mesa Laboratories Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, December 16th. Stockholders of record on Friday, November 29th were paid a $0.16 dividend. The ex-dividend date was Friday, November 29th. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.48%. Mesa Laboratories’s payout ratio is currently -1.40%.

Analyst Ratings Changes

A number of research firms have issued reports on MLAB. Evercore ISI raised their price target on shares of Mesa Laboratories from $120.00 to $160.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. StockNews.com lowered Mesa Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, November 13th.

Insider Buying and Selling

In other news, CEO Gary M. Owens sold 2,518 shares of the company’s stock in a transaction dated Monday, October 28th. The stock was sold at an average price of $113.62, for a total value of $286,095.16. Following the sale, the chief executive officer now owns 45,888 shares in the company, valued at $5,213,794.56. This represents a 5.20 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 4.40% of the stock is currently owned by corporate insiders.

About Mesa Laboratories

Mesa Laboratories, Inc develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.